Drug discovery basato sul controllo della ferroptosi per tumori e malattie neurodegenerative (lead FC-004), spin-off Keio.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series A FerroptoCure raised 960 million yen in a Series A (460 equity from ANRI, TUS Innovation Capital and others, plus 500 in AMED grants). | $6.2M |